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Abstract 
Human  matrix  metalloproteinase-26  (MMP-26/endometase/matrilysin-2)  is  a  putative  bi-
omarker for carcinomas of breast, prostate, and other cancers of epithelial origin. MMP-26 
expression was silenced using small interfering RNA (siRNA) in the human breast cancer cell 
line MDA-MB-231. Immunological and proteomics approaches, including two-dimensional gel 
electrophoresis  and  matrix  assisted  laser  desorption/ionization  time-of-flight  mass  spec-
trometry, were employed to identify differential protein expression in MMP-26 knockdown 
cells. A comparison of the protein expression profiles of control and MMP-26 knockdown 
cells revealed nine differentially regulated proteins. Five of the proteins (heat shock protein 90, 
glucose-regulated protein 78 (GRP78), annexin V, tropomyosin, and peroxiredoxin II) were 
up-regulated,  while  alpha-tubulin,  cystatin  SA-III,  breast  cancer  metastasis  suppressor  1 
(BRMS1) and beta-actin were down-regulated. This decrease of BRMS1 expression is con-
comitant with an increase of invasion through matrix-coated membranes. These results 
suggest an important role for MMP-26 in the regulation of proteins involved in invasive and 
metastatic breast cancers. 
Key words: Matrix metalloproteinase (MMP), MMP-26, breast cancer metastasis suppressor 1, pu-
tative protein biomarkers, invasion and metastasis, mass spectrometry, proteomics 
Introduction 
During past decades, studies have indicated that 
matrix  metalloproteinases  (MMPs)  participate  in  a 
number  of  physiological  processes  including  repro-
duction,  development,  morphogenesis,  and  tissue 
remodeling as well as several pathological conditions 
including arthritis, cardiovascular diseases, and can-
cer  metastasis  [1-3].  MMPs  were  believed  to  be  in-
volved  in  these  processes  solely  by  their  ability  to 
degrade extracellular matrix (ECM). Later however, it 
was demonstrated that in few cases MMPs might not Journal of Cancer 2011, 2 
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be required for tumor cells to invade tissue as shown 
by their ability to invade and move through an intact 
ECM by adopting amoeba-like movements, a process 
independent  of  MMPs  [4,  5].  Complexed  by  the 
number of studies involving this family of enzymes, 
MMP  activities  today  include  the  release  and  pro-
cessing  of  cryptic  fragments,  neo-epitopes,  growth 
factors,  growth  factor  receptors,  cytokines,  chemo-
kines,  and  precursor  proteins  from  matrix  and 
non-matrix substrates, as well as microenvironmen-
tal-dependent modification of the cell-ECM interface 
[1, 2, 6-8]. Most recently, the expression of MMPs can 
be  a  prognostic  marker  correlated  with  aggressive 
stages of cancer [9-11].  
Human  matrix  metalloproteinase-26 
(MMP-26/endometase/matrilysin-2),  comprised  of 
only  pro-  and  catalytic  domains,  is  the  smallest 
member of the MMP family with its tertiary structure 
and  enzymatic  activity  regulated  by  a  calcium  ion 
[12-15]. MMP-26 promotes invasion of a highly meta-
static  and  tumorigenic  prostate  cancer  cell  [16]. Ex-
pression of MMP-26 is significantly higher in prein-
vasive human breast ductal carcinoma in situ (DCIS) 
and  high-grade  prostatic  intraepithelial  neoplasia 
(HGPIN) when compared with that in normal human 
breast tissue samples and non-neoplastic ducts [11, 17, 
18].  Levels  of  MMP-26  expression  are  also  high  in 
early stage invasive carcinoma (I, II), whereas in stage 
III invasive carcinomas the level of MMP-26 decreases 
[11,  17].  A  similar  expression  pattern  has  been  dis-
covered  in  squamous  cell  cancer  (SCC)  where 
low-grade  SCC  correlated  to  increased  MMP-26  ex-
pression and lowered expression in dedifferentiated 
grade III tumors (9). MMP-26 has been postulated as a 
putative biomarker for human carcinomas of breast, 
prostate, and other cancers of epithelial origin [9, 11, 
17, 18].  
We undertook a proteomic approach to identify 
proteins  that  are  regulated  directly  or  indirectly  by 
MMP-26. In the present study, we utilized siRNA to 
knockdown expression of endogenous MMP-26 in the 
human breast cancer cell line MDA-MB-231. Changes 
of  the  protein  expression  pattern  in  MDA-MB-231 
were  investigated  by  two-dimensional  gel  electro-
phoresis (2-DE). The proteins in question were identi-
fied  by  matrix  assisted  laser  desorption/ionization 
time-of-flight  mass  spectrometry  (MALDI-TOF  MS) 
and Western blots were utilized to confirm changes of 
protein  expression  upon  silencing  MMP-26  expres-
sion. 
Material and Methods 
Construction of MMP-26 Specific siRNA con-
taining  vector-  The  construction  of  the  siR-
NA-expression  plasmids  was  based  on  siSTRIKE™ 
U6 Hairpin Cloning Systems (Promega Corporation). 
The vector includes a human U6 promoter, Ampr / 
Neomycinr  genes,  and  facilitated  sticky  ends  with 
downstream overhang PstI partial sites. The inserted 
hairpin  sequence,  which  is  sense  nucleotides,  a 
loop-creating region, and anti-sense nucleotides, was 
designed  by  using  the  siRNA  Target  Designer  Pro-
gram  (www.promega.com/siRNADesigner/).  The 
sequences generated by this program were compared 
to all sequences in Genbank by using NCBI BLAST to 
confirm  the  specificity  for  MMP-26.  Among  those 
sequences, only the MMP-26 specific target sequence 
was selected and also a scrambled sequence was de-
signed in the same manner as the control. Forward 
and  reverse  sequences  of  siRNA  target  insert  and 
scramble  insert  were,  respectively,  as  follows: 
MMP-26  target,  5'-ACCGGAAGATGCAAGTG 
GAATAAAGTTCTCTTATTCCACTTGCATCTTCCT
TTTTC  -3'  and  5'-TGCAGAAAAAGGA 
AGATGCAAGTGGAATAAGAGAACTTTATTCCA
CTTGCATCTTC  -3';  scrambled  target, 
5'-ACCGATAGTGAACGGTAAGAAGAAGTTCTCT
CTTCTTACCGTTCACTATCTTTTTC  -3'  and 
5'-TGCAGAAAAAGATAGTGAACGGTAAGAAGA
GAGAACTTCTTCTTACCGTTCACTAT -3'.  
After annealing, the DNA fragment was ligated. 
The one new PstI site  produced by ligation and al-
ready existing PstI site were used for the selection of 
siSTRIKE™/MMP-26  or  siSTRIKETM/scrambled 
plasmids. 
Cell culture, transfection of MDA-MB-231 cells 
and isolation of cell lines containing MMP-26 spe-
cific  siRNA-  MDA-MB-231  (ATCC),  an  established 
human  breast  carcinoma  cell  line,  was  routinely 
grown in polystyrene tissue culture dishes (100 x 20 
mm,  Becton  Dickinson  Labware)  with  high-glucose 
Dulbecco’s modified Eagle’s Medium (DMEM, Gibco 
Invitrogen Corporation) supplemented with 10% fetal 
bovine serum (FBS, Hyclone), 100 units/mL penicil-
lin, and 100 g/mL streptomycin (Cambrex) in a hu-
midified  atmosphere  containing  5%  CO2  at  37C. 
MDA-MB-231  cells  were  transfected  with 
siSTRIKE™/MMP-26  or  siSTRIKETM/scrambled  us-
ing Transfectol (GeneChoice, PGC Scientifics Corpo-
ration). Transfectol-mediated DNA transfections into 
MDA-MB-231  cells  were  performed  following  the 
instructions provided by GeneChoice. Transfected cell 
lines were maintained in the presence of 550 g/mL 
Geneticin (G-418, Fisher Science), and were screened 
on the basis of down-regulation of MMP-26 expres-
sion. Selected stably transfected cell lines were main-
tained in G-418 due to rapid loss of vector in the ab-
sence of selection pressure. Journal of Cancer 2011, 2 
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Immunoblotting-  At  confluence,  cells  were 
washed  three  times  with  phosphate  buffered  saline 
(PBS).  Each  dish  was  treated  with  1  mL  of  0.25% 
trypsin  solution  (GIBCO  Invitrogen  Corporation), 
mixed  with  9  mL  of  serum  free  DMEM  and  cell 
number was determined using a hemacytometer. Cell 
lysates were collected according to the manufacturer’s 
protocol  (Pierce).  Briefly,  cells  were  washed  three 
times  with  PBS,  an  appropriate  amount  of  M-PER 
(Pierce) reagent and protease inhibitor cocktail (Sig-
ma) was added to adjust 107 cells/mL. After 5 min 
gentle shaking, cells were removed with a scraper and 
transferred to a microfuge tube. The protein concen-
tration (1.58 mg/mL)  was determined by using  the 
BCA  protein  assay  kit  (Pierce).  Protein  (35  g)  was 
separated by sodium dodecyl sulfate polyacrylamide 
gel electrophoresis (SDS-PAGE) in a 10% polyacryla-
mide gel and was then transferred to a BioTrace NT 
nitrocellulose  membrane  (Pall  Life  Science).  The 
membrane was blocked with 5% w/v bovine serum 
albumin  (BSA,  Sigma-Aldrich)  in  TBST  (100  mM 
Tris/HCl, pH 7.4, 150 mM NaCl,  20  mM  KCl,  0.05% 
Tween 20) for 2 h at room temperature and then in-
cubated  with  primary  antibody  for  another  2  h  at 
room temperature. The primary antibodies used were 
as follows: rabbit anti-human MMP-26 polyclonal and 
mouse  anti-human  BRMS1  monoclonal  antibodies 
were  prepared  as  described  before  [11,  19];  mouse 
anti-human cystatin SA  monoclonal antibody (R&D 
Systems);  all  other  primary  antibodies  (rabbit  an-
ti-human  90kDa  HSP  polyclonal  antibody,  goat  an-
ti-human  GRP78  polyclonal  antibody,  goat  an-
ti-human  peroxiredoxin  II  (PRX  II)  polyclonal  anti-
body,  goat  anti-human  annexin  V  polyclonal  anti-
body, and goat anti-human tropomyosin polyclonal 
antibody) were purchased from Santa Cruz Biotech-
nology. After three washes with TBST, the membrane 
was incubated with alkaline phosphatase conjugated 
secondary antibody for 30 min at room temperature. 
The bands were visualized by NBT/BCIP substrates. 
Two-dimensional  gel  electrophoresis-  Cells 
grown to confluence were washed three times with 
PBS. A single 100-mm cell culture dish was lysed by 
adding  an  appropriate  amount  of  2D-lysis  buffer 
containing 7 M urea, 2 M thiourea, 2% w/v CHAPS, 
0.25%  w/v  Biolyte  3-10  ampholyte  (Bio-Rad)  and 
protease inhibitor cocktail (Sigma), and 1% w/v DTT 
to the dish containing the cells (107 cells/mL). Cells 
were removed with a scraper, transferred to a centri-
fuge tube, and sonicated for 2 min in an ice bath fol-
lowed by centrifugation at 17,000 x g for 20 min/4C. 
The supernatant was transferred to a clean tube, and 
protein concentration was determined using the BCA 
protein assay kit (Pierce). After addition of 2D-lysis 
buffer (ca. 50 L) containing a trace amount of bro-
mophenol blue to cell lysates (200 g), the sample was 
vortexed for 1 h at room temperature and centrifuged 
(1,000 x g for 5 min). The resultant supernatant was 
applied to immobilized pH gradient (IPG) strips (pH 
4-7, 11 cm, Bio-Rad). After 12 h of active rehydration 
(50 V)  at 20C, the proteins in the  sample  were fo-
cused at 250 V for 15 min with a final voltage of 8000 
V  for  a  total  of  60,000  volt-hours.  The  strips  were 
subsequently equilibrated for 10 min in 2 mL of solu-
tion consisting of 6 M urea, 2% w/v SDS, 375 mM 
Tris/HCl  (pH  8.8),  2%  w/v  DTT  and  20%  glycerol 
followed by another 10 min equilibration with 2 mL of 
solution containing 375 mM Tris/HCl (pH 8.8), 6 M 
urea,  2%  w/v  SDS,  2.5%  w/v  iodoacetamide,  and 
0.1% w/v bromophenol blue. Equilibrated IPG strips 
were transferred onto 10% polyacrylamide gels casted 
in-house in 2D gel Criterion cassette (Bio-Rad) with 
the proteins separated by SDS-PAGE (100 V for 5 h) at 
4C. Separated proteins were visualized by EZ-Blue 
staining solution (Sigma). SeeBlue Plus2 pre-stained 
standard  (Invitrogen)  was  used  to  determine  ap-
proximate  molecular  weight  of  protein  spot  while 
spot size was measured by Integrated Morphometry 
Analysis (IMA) followed by statistical analyses. Data 
were expressed as means ± standard deviation (SD). 
P-values  of  <  0.05  were  considered  statistically  sig-
nificant. 
Protein identification by in-gel trypsin diges-
tion and MALDI-TOF MS- The protein spots of in-
terest  were  manually  excised  with  cut  pipette  tips 
from the stained 2D gels and transferred to siliconized 
tubes (0.6 mL). The gel plugs were trypsin digested 
using in-gel trypsin digestion kit (Pierce). Briefly, the 
gel plugs were dehydrated (15 min) by adding 50 L 
of acetonitrile (ACN). ACN was then removed and gel 
plugs were dried. The gel plugs were digested with 
trypsin (10 L of 10 ng/L trypsin solution) at 30 C 
overnight with constant shaking. Thereafter, the su-
pernatant containing tryptic peptides was transferred 
to another  siliconized tube. The peptides in  the  gel 
plug were extracted (5 min) with  1% trifluoroacetic 
acid (10 L) and the supernatant was pooled. Tryptic 
peptides  were  desalted  with  ZipTipC18  (Millipore 
Corporation),  mixed  with  al-
pha-cyano-4-hydroxycinnamic  acid  (CHCA,  Sigma), 
and spotted onto a MALDI target plate. The tryptic 
peptides  were  analyzed  with  a  MALDI-TOF  mass 
spectrometer (Axima CFRplus, Shimadzu Corporation) 
by  Kompact  v.2.4.1  software.  The  acquired  masses 
were  calibrated  with  ProteoMassTM  Peptide 
MALDI-MS calibration kit (Sigma) as external refer-
ence masses and trypsin auto-digested peptides (m/z 
515.33, 842.51, 2211.10) as internal references masses. Journal of Cancer 2011, 2 
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Spectra  were  acquired  in  the  reflection  mode.  The 
tryptic peptide ((M+H)+) masses were used to search 
the  database.  The  database  search  was  performed 
online  with  Mascot  server  (http://www. 
matrixscience.com/cgi/search_form.pl?FORMVER=2 
&SEARCH=PMF). Carbamidomethylation of cysteine 
was selected for the fixed modification. The NCBInr 
database was searched within a mass tolerance of ± 
100 ppm for human proteins, allowing for one missed 
cleavage. Proteins were considered to be successfully 
identified by the following parameters - peptide tol-
erance lower than ± 100 ppm. Mowse score greater 
than 68, low probability that the observed match be-
tween  the  experimental  data  and  the  database  se-
quence is a random event, number of matched pep-
tides and percent coverage. A false positive identifi-
cation was evaluated by searching a decoy database. 
Modified  Boyden  chamber  invasion  assays- 
The invasiveness of wild type and siRNA transfected 
MDA-MB-231  cells  through  reconstituted  ECM  was 
determined as described previously [12]. Briefly, in-
vasion inserts containing polycarbonate filters with 8 
m pores (BD Biosciences) were coated with 70 L of 
250 g/mL of Type IV collagen (Sigma). The Boyden 
chambers were dried and sterilized in a laminar flow 
hood under ultraviolet radiation overnight. To com-
mence the assay, 500 L of DMEM high-glucose cul-
ture medium containing 10% v/v FBS was added to 
the lower chambers, and 300 L of prepared cell sus-
pensions (1.5 x 105 cells/mL) in  serum free DMEM 
high glucose media was added to each insert. After 12 
h  of  incubation,  invasive  cells  that  had  passed 
through the filter to the lower surface of the mem-
brane were stained using a 0.1% w/v crystal violet 
solution.  Cells  remaining  inside  the  chamber  were 
removed with a cotton swab, and the filters were re-
moved  and  mounted  on  a  microscope  slide.  The 
membranes  were  photographed  with  an  Olympus 
DP10 digital camera (Melville) under a Nikon FX Mi-
croscope (Melville). Cells were counted by IMA. For 
statistical analyses  wild type MDA-MB-231 cell line 
was assumed to reflect 100% cell invasion. The ratio of 
the number of invaded cells of each cell line to the 
invaded cells of the wild type MDA-MB-231 cell line 
was used for subsequent comparative analyses. Val-
ues are mean ± SD of triplicate experiments. A dif-
ference in ratio was considered statistically significant 
at p < 0.05. 
Results 
Silencing expression of MMP-26 by using small 
interfering RNA in MDA-MB-231 cells 
Utilizing  siRNA  the  endogenous  expression  of 
MMP-26  was  knocked-down  in  the  MDA-MB-231 
human breast carcinoma cell line. Cell clones in which 
MMP-26  expression  was  knocked-down  most  com-
pletely  by  siSTRIKE™/MMP-26  was  assessed  by 
immunoblot  (Figure  1).  A  scrambled  siRNA  trans-
fected cell line was used to control for off target siR-
NA  effects.  Furthermore,  MMP-26  knock-down  cell 
line also showed a dramatic decrease of BRMS1 ex-
pression. 
 
 
Figure  1.  Blocking  expression  of  MMP-26  in 
MDA-MB-231  cell  line  silenced  expression  of 
BRMS1.  (A)  10%  SDS-PAGE  followed  by  immunoblot 
analyses  using  anti-MMP-26.  siRNA,  interfering  with  the 
mRNA of MMP-26, silenced expression of MMP-26 com-
pared with parental and scrambled siRNA transfected cell 
lines.  Purified  recombinant  MMP-26  control,  which  was 
expressed in BL21 (DE3)-competent  E. coli  cells and re-
folded as described previously (Lee et al 2007). (B) 10% 
SDS-PAGE  followed  by  immunoblot  analyses  using  an-
ti-BRMS1 antibody. Blocking of MMP-26 mRNA silenced 
expression of BRMS1 compared with parental and scram-
bled  siRNA  transfected  cell  lines.  Purified  recombinant 
MMP-26 control. 
 
Identification of protein expression changes by 
MALDI-TOF spectroscopy and immunoblotting 
in MMP-26 knockdown MDA-MB-231 cells 
2-DE of MMP-26 or scrambled siRNA transfect-
ed MDA-MB-231 cells showed changes of the expres-
sion pattern. Only identified protein spots were des-
ignated by arrows (Figure 2A). Silencing of MMP-26 
modified the expression of eight different spots. Spots 
designated  by  si1/scr1,  si2/scr2,  si4/scr4.  si5/scr5 
and si6 where 5 proteins shown to increase their ex-
pression. While si3/scr3, si7/scr7 and si8/scr8 were 
down-regulated  by  MMP-26  knockdown.  Figure  2B 
shows detailed spot areas. Detailed area for si4/scr4 
was observed from another set of 2-DE gels. Figure 2C 
shows statistically analyzed protein expression level. 
MMP-26  knockdown  caused  five  significantly  in-
creased  expression  levels  of  proteins  (si1/scr1, 
si2/scr2, si4/scr4, si5/scr5, and si6) and three signif-
icantly  decreased  expression  of  proteins  (si3/scr3, 
si7/scr7, and si8/scr8).  Journal of Cancer 2011, 2 
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Figure 2. Representative images of two dimensional gel electrophoresis of cell lysate. (A) 250 g of whole 
MDA-MB-231 cell lysate using 11 cm, 4 to 7 pH range IPG strips in the first dimension and 10 % polyacrylamide gel in the 
second dimension were used. Gels were visualized by using EZ Blue. Blocking expression of MMP-26 by siRNA showed a 
differential expression pattern. Spots identified successfully by MALDI-TOF MS were the only ones labeled. (B) Cropped 
images were obtained from same 2D gel except for si7/scr7 which were obtained from another pair of 2D gels. (C) Spot 
sizes were measured by IMA. MMP-26 knockdown MDA-MB-231 cell line showed significantly increased expression of 
HSP90 (si1/scr1, p < 0.0005), GRP78 (si2/scr2, p < 0.0005), annexin V (si4/scr4, p < 0.0005), tropomyosin (si5/scr5, p < 
0.05), and PRX II (si6, no p value due to no spot for scramble detected), and significantly decreased expression of α-tubulin 
(si3/scr3, p < 0.0005), cystatin SA (si7, p < 0.05), and β-actin (si8/scr8, p < 0.005). 
 
 
 
 
Table  1  shows  identified  protein  spots  by 
MALDI-TOF  spectroscopy  (si1/scr1,  90  kDa  heat 
shock protein A (HSP90A), Mowse score =  143, se-
quence  coverage  =  36%;  si2/scr2,  GRP  78,  Mowse 
score  =  185,  sequence  coverage  =  31%;  si3/scr3, 
-tubulin, Mowse score = 140, sequence coverage = 
49%;  si4/scr4,  annexin  V,  Mowse  score  =243,  se-
quence  coverage  =  68%;  si5/scr5,  tropomyosin, 
Mowse  score  =  117,  sequence  coverage  =  31%;  si6, 
peroxiredoxin II (PRX II), Mowse score = 77, sequence 
coverage = 26%; si7/scr7, cystatin SA, Mowse score = 
117,  sequence  coverage  =  68%;  si8/scr8,  -actin, 
Mowse score =88, sequence coverage = 26%). Figure 3 
and  Figure S1 shows the  mass spectra of identified 
proteins. Western blot analysis supported 2-DE anal-
ysis  data.  MMP-26  knock-down  MDA-MB-231  cell 
line showed increased expression of HSP90, GRP78, 
annexin V, tropomyosin, and PRX II (Figure 4). Vali-
dation of down-regulated proteins could not be de-
termined by western blot due to the presence of non-
specific bands. 
 Journal of Cancer 2011, 2 
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Table 1. Identification of proteins which are differentially expressed upon treatment with MMP-26 specific 
siRNA. Protein spots were excised from 2D gels, in-gel trypsin digested, desalted using ZipTip C18, and identified by 
MALDI-TOF MS. Five identified proteins (HSP90, GRP78, annexin V, tropomyosin, PRX II) were upregulated and three 
identified proteins (-tubulin, cystatin, -actin) were downregulated in MMP-26 specific siRNA transfected MDA-MB-231 
cells compared with control (scrambled siRNA transfected cells). 
Spot  Identification  NCBInr 
Accession # 
Theoretical 
Mr (103) /pI 
Experimental 
Mr (103) /pI 
Score  Expect  Peptide 
# 
% Coverage 
si1/scr1  HSP90A  NP_001017963  85/4.94  100/5.74  143  1e-10  24  36 
si2/scr2  GRP78  P07823  72.4/5.07  80/5.47  185  6.5e-15  20  31 
si3/scr3  -Tubulin  CAA25855  50.8/5.02  55/5.68  140  2.2e-09  17  49 
si4/scr4  Annexin V  NP_001145  36.0/4.94  35/5.32  243  1.1e-19  20  68 
si5/scr5  Tropomyosin  NP_001036817  29.1/4.79  32/5.05  117  3.1e-07  10  31 
si6  PRX II  NP_005800  21.9/5.67  25/6.22  77  2.9e-3  5  26 
si7/scr7  Cystatin-SA  NP_001890  16.5/4.95  14/4.8  117  4.1e-08  10  68 
si8/scr8  -Actin  AAH12854  40.5/5.55  45/5.95  88  2.8e-4  8  26 
 
 
 
 
 
 
Figure  3.  MALDI-TOF  mass  spectra  of 
GRP78, annexin V and cystatin. The protein 
spots  were  excised  from  2DE  gel,  in-gel 
trypsin digested, ZipTip purified, and were 
analyzed with MALDI-TOF MS. Tryptic (P), 
and  trypsin  autodigestion  (T)  peptides  are 
indicated in the spectrum. 
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Figure 4. Western blot analysis. The MALDI-TOF MS identified proteins were validated by immunoblotting. Silencing 
MMP-26 expression showed the differential expression level of the proteins, HSP90 (100 kDa), GRP78 (82 kDa), annexin V 
(double bands around 36 kDa), tropomyosin (32 kDa), and PRX II (24 kDa). Only up-regulated proteins were identified by 
western blot. It was not be able to determine down regulated protein because of the heavy nonspecific bands.  
 
Silencing expression of MMP-26 increases inva-
sion by MDA-MB-231 cells 
To initially assess biological changes associated 
with siRNA knock-down of MMP-26, three cell lines 
(parental,  MMP-26  target-  or  scrambled  siRNA- 
transfected  MDA-MB-231  cell  lines)  were  evaluated 
for invasion through type IV collagen-coated filters. 
Lack of MMP-26 in MDA-MB-231 cells showed a sta-
tistically  significant  increase  of  invasion  potential 
through  a  type  IV  collagen-coated  membrane; 
whereas, scrambled siRNA-transfected cells showed 
insignificant  change  of  invasion  potential  when 
compared with the parental cell line (wild vs. siRNA, 
p  <  0.005;  scramble  vs.  siRNA,  p  <  0.005;  wild  vs. 
scramble, p > 0.05) (Figure 5).  
 
Figure  5.  Change  of  invasive  potential  of 
MDA-MB-231  cells  according  to  the  transfection 
with MMP-26  siRNA. Invasion assays were performed 
with  modified  Boyden  chambers,  and  the  percentage  of 
invading cells was quantified as described under “Experi-
mental Procedures”. All error bars shown are SD from the 
mean of triplicate experiments for each group.  MMP-26 
siRNA transfected cell line showed statistically significant 
increase in invasion potential (p < 0.005 compared with wild 
type and control (scrambled siRNA transfected cell line)). 
The asterisk denotes statistically significant.  
 
Discussion 
Human  endometase,  also  known  as  matri-
lysin-2/MMP-26, is a putative biomarker for various 
preinvasive cancers [9, 11, 17, 18]. Past studies have 
demonstrated that in contrast with the other secretory 
MMPs,  MMP-26  is  predominantly  intracellular,  de-
spite the presence of the signal peptide in MMP-26’s 
prodomain  [13-16,  20].  Western  blot  analysis  of 
MDA-MB-231 cell lysate indicated high levels of in-
tracellular MMP26, while expression of enzyme was 
not  detected  in  the  cell  culture  medium  (data  not 
shown).  We  began  to  explore  MMP-26  as  an  an-
ti-tumor or anti-invasion protein. Selectively blocking 
of MMP-26 expression by siRNA resulted in increased 
invasiveness  and  changes  in  expression  of  several 
proteins associated with invasion and/or metastasis, 
especially silencing BRMS1 expression.  
BRMS1 is a suppressor of metastasis for human 
breast  cancer  [21-23],  melanoma  [24],  ovarian  carci-
noma [25] and non-small cell lung cancer [26]. Micro-
array  and  proteomics  analyses  showed  multiple 
changes in gene and protein expression when BRMS1 
was re-expressed [27, 28]. BRMS1 has been proposed 
to  regulate  gene  transcription  through  interaction 
with  large  SIN3:HDAC  complexes  [21,  29]  and 
through  negative  regulation  of  NF-B  [30].  Im-
portantly,  BRMS1  reduced  invasion  through  Mat-
rigel-coated filters [23]. 
The 2D-gel, MALDI-TOF MS analyses revealed 
that silencing MMP-26 expression also  modifies the 
regulation  of  additional  proteins  which  have  been 
implicated  in  tumor  growth,  invasion,  motility  and 
metastasis.  For  example,  the  five  up-regulated  pro-
teins include HSP90, GRP78, annexin V, tropomyosin 
and PRXII, while three down-regulated proteins are Journal of Cancer 2011, 2 
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composed of -actin, -tubulin and cystatin SA-III. 
Heat shock protein (HSP) and glucose regulated 
protein (GRP) are molecular chaperones involved in 
proper  folding  of  nascent  polypeptides, 
post-translational  regulation  of  signaling  molecules 
and  reducing  apoptosis  under  the  stress  [31-34]. 
However, these characteristics of chaperones endow 
tumor cells to survive under stressful microenviron-
ments [35, 36]. HSP90’s client proteins are involved in 
malignant phenotypes including uncontrolled prolif-
eration,  immortalization,  impaired  apoptosis,  and 
angiogenesis [36, 37]. However, not all client proteins 
are involved in cancer progression. Yet, BRMS1 was 
identified  as  a  client  protein  of  HSP90  [19].  Recent 
research revealed that HSP90 stabilizes and activates 
cell  surface  receptors  by  its  interactions  with  extra-
cellular and cytoplasmic domain of receptors to facil-
itate  cell  migration  [38-41].  HSP90  has  been  recog-
nized as a target for the treatment of cancer [36, 42]. 
Elevated  expression  of  HSP90  has  been  reported  in 
various leukemia cases and a number of tumor types 
including  breast,  lung  along  with  other  high-grade 
malignant tumors [43, 44]. GRP78 also has been re-
ported to be up-regulated in a variety of cancer cell 
lines, solid tumors, and human cancer biopsies corre-
lating with malignancy [45-48].  
Peroxiredoxins (PRXs), a novel group of cyste-
ine-containing proteins with efficient antioxidant ca-
pacity [49], are involved in signal transduction, cell 
proliferation, differentiation, apoptosis, and gene ex-
pression [50, 51]. PRX II, a member of PRX family, is a 
cytosolic protein. PRX II is known to not only protect 
cells from oxidative damage caused by H2O2, but also 
to  endow  cancer  cells  with  resistance  to  both  H2O2 
and cisplatin granting them radioresistance [52]. The 
expression level of PRX II is very high in malignant 
mesothelioma compared with healthy pleural meso-
thelium  [53,  54].  Recent  proteomic  profiling  shows 
that  progressive  cancer  cells  overexpress  PRX  II 
compared with regressive cancer cells [52]. 
Annexins are a family of proteins which bind to 
negatively  charged  phospholipids  in  a  calci-
um-dependent  manner.  Annexin  V  forms  voltage 
sensitive  channels  [55]  and  mediates  calcium  flux, 
phospholipid-dependent inhibition of blood coagula-
tion, modulation of protein kinase C, and the inhibi-
tion of phospholipase A2 activity [55, 56]. Cancer re-
lated research shows that the expression of annexin V 
is augmented in growth hormone-secreting carcino-
mas [57] while proteomics profiling shows that pro-
gressive cancer cells overexpress annexin V compared 
with regressive cancer cells [52]. 
Tropomyosins encompass a large family of actin 
regulatory proteins that stabilize the actin cytoskele-
ton and regulate actin-myosin interactions during cell 
migration  [58-60].  Tropomyosin  destabilizes  actin 
filaments and is expressed more in highly metastatic 
cells than low ones. Moreover, suppression of tropo-
myosin  in  the  highly  metastatic  cell  line  results  in 
suppression of cell motility [61].  
Actin and its associated proteins play important 
structural and functional roles, such as maintaining 
cell morphology, cell adhesion, cell motility, exocyto-
sis,  endocytosis,  and  cell  division  [62,  63].  When 
mammalian  cells  are  transformed  or  progressed  to 
acquire  metastatic  potential,  the  expression  of  actin 
and/or  actin-related  proteins  becomes  modified. 
-actin  is  present  in  non-muscle  cells,  especially  in 
submembrane, and  participates in active cell move-
ment and wound healing [64].  
Tubulin, the building block of microtubules, is a 
heterodimmer  comprising  alpha  and  beta  subunits, 
each approximately 50 kDa. Microtubules are the es-
sential components of all eukaryotic cells and are in-
volved  in  a  diverse  range  of  cellular  functions,  in-
cluding motility [65, 66]. Disruption of the microtu-
bule  network  through  incorporation  of  nitrotyro-
sinated -tubulin results in apoptosis and inhibition 
of myogenic differentiation. Modification of the tubu-
lin may play a role in multi-drug resistance to chem-
otherapy and it is a key molecular target for cancer 
therapy [67]. MDA-MB-231 breast cancer cells contain 
only  tyrosinated  tubulin  and  low  level  monoglu-
tamylation in certain isoforms [65]. Tubulin detyro-
sination also has been reported in breast cancer and is 
linked to tumor aggressiveness [68]. 
Cystatins  are  endogenous  cysteine  proteinase 
inhibitors that are found in body fluids and tissues. 
They are generally tight-binding inhibitors of cysteine 
proteinases such as papain, ficin, and cathepsins. The 
physiological functions of cystatins are regulation of 
protein  metabolism,  protection  of  cells  and  tissues 
against  unfavorable  proteolysis,  and  tissue  damage 
[69].  Cystatin  SA  is  abundant  in  human  saliva  and 
known to be expressed tissue-specifically [70].  
Recent proteomics profiling shows that progres-
sive cancer cells overexpress HSP90, annexin V, PRX 
II, and tropomyosin compared with regressive cancer 
cells  [52].  Other  individual  researchers  have  shown 
the role of these in carcinomas. HSP90 promotes in-
vasive  potential  through  activating  proMMP-2  [71], 
and expression level of PRX II is very high in malig-
nant  mesothelioma  compared  with  healthy  pleural 
mesothelium [49, 53]. Suppression of tropomyosin in 
the highly metastatic cell line results in suppression of 
cell  motility  [61].  Therefore,  previous  results  show 
that  HSP90,  annexin  V,  PRX  II,  tropomyosin,  and 
β-actin are all involved in invasive potential and/or Journal of Cancer 2011, 2 
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metastatic  phenotypes  of  cancer  cells.  Anti-tumor 
properties  of  MMP-26  also  have  been  studied. 
MMP-26-mediated, intracellular pathway targets ER 
and MMP-26 contributes favorably to the survival of 
the  ER/-positive  cohort  of  breast  cancer  patients 
[72].  Taken  together  with  our  results,  MMP-26 
down-regulates several proteins enabling cancer cell 
to  be  invasive  supporting  anti-tumor  function  of 
MMP-26.  
In summary, silencing MMP-26 in MDA-MB-231 
cells increased invasion commensurate with changes 
in  invasion-associated  protein  expression.  These  re-
sults directly correspond to our previously reported 
studies  showing  that  MMP-26  expression  is  signifi-
cantly higher in preinvasive DCIS and HGPIN, com-
pared with normal breast, non-neoplastic ducts, and 
invasive  carcinomas  [11,  18].  While  there  may  be 
context-dependent  differences  in  the  role(s)  of 
MMP-26 [16], the data suggest that MMP-26 may be a 
useful biomarker for premalignant carcinomas.  
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Figures 
 
Figure S1. MALDI-TOF mass spectra of HSP90A, tropomyosin, tubulin, PRX II, and actin. The protein spots were excised 
from 2DE gel, in-gel trypsin digested, ZipTip purified, and were analyzed with MALDI-TOF MS. 
 